Zidovudine (AZT) for Treatment of Patients Infected With Human Immunodeficiency Virus Type 1: An Evaluation of Effectiveness in Clinical Practice
Colson E, Horwitz R, Bia F, Viscoli C. Zidovudine (AZT) for Treatment of Patients Infected With Human Immunodeficiency Virus Type 1: An Evaluation of Effectiveness in Clinical Practice. JAMA Internal Medicine 1991, 151: 709-713. DOI: 10.1001/archinte.1991.00400040061014.Peer-Reviewed Original ResearchZidovudine therapyDosage reductionAdverse outcomesHuman immunodeficiency virus type 1 (HIV-1) infectionClinical practiceHuman immunodeficiency virus type 1Virus type 1 infectionImmunodeficiency virus type 1Observational cohort studyHuman immunodeficiency virusTreatment of patientsType 1 infectionVirus type 1Zidovudine dosageCohort studyMost patientsImmunodeficiency virusBaseline cytopeniasTreatment outcomesPatterns of usePatientsTherapyType 1Dosage changesMonthsZidovudine (AZT) for treatment of patients infected with human immunodeficiency virus type 1. An evaluation of effectiveness in clinical practice.
Colson ER, Horwitz RI, Bia FJ, Viscoli CM. Zidovudine (AZT) for treatment of patients infected with human immunodeficiency virus type 1. An evaluation of effectiveness in clinical practice. JAMA Internal Medicine 1991, 151: 709-13. PMID: 2012453, DOI: 10.1001/archinte.151.4.709.Peer-Reviewed Original ResearchConceptsZidovudine therapyDosage reductionAdverse outcomesHuman immunodeficiency virus type 1 (HIV-1) infectionClinical practiceHuman immunodeficiency virus type 1Virus type 1 infectionImmunodeficiency virus type 1Observational cohort studyHuman immunodeficiency virusTreatment of patientsType 1 infectionVirus type 1Zidovudine dosageCohort studyMost patientsImmunodeficiency virusBaseline cytopeniasTreatment outcomesPatterns of usePatientsTherapyType 1Dosage changesMonths
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply